SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Rigel Pharmaceuticals, Inc. (RIGL)
An SI Board Since November 2000
Posts SubjectMarks Bans Symbol
566 39 0 RIGL
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
316Thanks Wilder. That's a good thing I assume??? lolmcbio-4/11/2007
315mcbio, let me be the first to PeopleMark you.keokalani'nui-4/11/2007
314More updating; biz.yahoo.com Cheers back at you Tuck - (nice individual touch!)Steve Lokness-4/11/2007
313Rigel recently highlighted its internal ubiquitin ligase program for HIV. Here&tuck-4/9/2007
312i have held the stock for a long time now, some trades in and out and a core posmopgcw-2/11/2007
311I think for a biotech with a sub $300 million market cap, RIGL has one of the nimcbio-2/10/2007
310Rigel Announces Fourth Quarter and Year End 2006 Financial Results SOUTH SAN FRAmopgcw-2/9/2007
309[R406: Syk is a protooncogene involved in the transformation of lymphocytes, thutuck-12/2/2006
308Rigel Announces Third Quarter 2006 Financial Results Tuesday November 7, 7:30 ammopgcw-11/7/2006
307I'm out for now.keokalani'nui-10/31/2006
306Thanks for the explanation! I doubt it will be important enough to fetch the patuck-10/2/2006
305Preramble..... there's something that I'm missing. So none of what fscaram(o)uche-10/2/2006
304Rigel Announces Initiation of Phase II Study Evaluating R788 in Rheumatoid Arthrmopgcw-9/6/2006
303>>J Pharmacol Exp Ther. 2006 Aug 31; [Epub ahead of print] R406, an Oraltuck-9/3/2006
302Rigel Announces Second Quarter 2006 Financial Results Wednesday August 2, 7:30 amopgcw-8/2/2006
301Rigel's Janus Kinase 3 (JAK3) Inhibitors Show Benefit in Organ Transplant Momopgcw-7/19/2006
300[R-253 disrupts microtubule networks in multiple tumor cell lines] >>Clintuck-6/18/2006
299Rigel Announces Pfizer Selection of R343, a Syk Kinase Inhibitor, for Advanced Pmopgcw-5/19/2006
298Rigel Announces First Quarter 2006 Financial Results Tuesday May 2, 7:30 am ET mopgcw-5/3/2006
297Rigel Granted Key Patents in Immunology, Virology and Oncology Tuesday March 21,mopgcw-3/31/2006
296[Preliminary data from PI for R788 for RA & ITP] >>SOUTH SAN FRANCISCtuck-2/22/2006
295[The novel Syk inhibitor R406 blocks JNK-mediated gene expression in synoviocytetuck-2/4/2006
294Rigel Achieves Milestone with Merck Ligase Collaboration Monday January 30, 7:30nigel bates-1/30/2006
293Serono INDs R763, the Aurora Kinase Inhibitor, Rigel gets $5 million milestone ptuck-1/26/2006
292- Initiates Methotrexate Interaction Trial of R788 in Rheumatoid Arthritis - LJM-12/20/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News